CYTK Analyst Estimates: Price Targets, Revenue, Net Income, and EBIT Forecast - Cytokinetics Inc - Alpha Spread

First Time Loading...

Watchlist Manager

Watchlist

Price: 65.34 USD 0.83%

Updated:

Section:

Wall Street
Price Targets

Wall Street analysts forecast CYTK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CYTK is 96.96 USD with a low forecast of 60.6 USD and a high forecast of 128.1 USD.

CYTK Lowest Forecast

Wall Street Target

CYTK Average Forecast

Wall Street Target

CYTK Highest Forecast

Wall Street Target

7% Downside

48% Upside

96% Upside

The latest public price target was made on Apr 5, 2024 by Salim Syed from Mizuho Securities , who expects CYTK stock to rise by 52% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst	Price Target	Date	Article
Salim Syed Mizuho Securities	99 USD Upside 52%	3 weeks ago Apr 5, 2024	Mizuho on Cytokinetics (CYTK) Presentation: 'OREST oHCM 48wk Data @ ACC '24 ==> Incremental +ive' StreetInsider

Price Target	99 USD
Upside/Downside	52%

Panacea Biotec Ltd

52% Downside

Hans Biomed Corp

182% Upside

Japan Tissue Engineering Co Ltd

85% Upside

Lepu Biopharma Co Ltd

25% Downside

Panacea Biotec Ltd

52% Downside

Hans Biomed Corp

182% Upside

Japan Tissue Engineering Co Ltd

85% Upside

Lepu Biopharma Co Ltd

25% Downside

Genenta Science SPA

806% Upside

Biotest AG

19% Downside

EuBiologics Co Ltd

12% Upside

SpringWorks Therapeutics Inc

50% Upside

Revenue
Forecast

For the last 8 years the compound annual growth rate for Cytokinetics Inc's revenue is -15%. The projected CAGR for the next 3 years is 313%.

-15%

313%

-6%

What are analyst estimates?

Operating Income
Forecast

N/A

N/A

0%

What are analyst estimates?

Net Income
Forecast

N/A

N/A

-41%

What are analyst estimates?

See Also

Relative Valuation

Wall Street Estimates

Profitability Analysis

Solvency Analysis

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

According to Wall Street analysts, the average 1-year price target for CYTK is 96.96 USD with a low forecast of 60.6 USD and a high forecast of 128.1 USD.

For the last 8 years the compound annual growth rate for Cytokinetics Inc's revenue is -15%. The projected CAGR for the next 3 years is 313%.

Join more than 132,500+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.